News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Results From a Phase 3 Study Show Iroko Pharmaceuticals’s Investigational Submicron Indomethacin Provided Effective Pain Relief at Lower Doses



12/7/2012 10:12:45 AM

PHILADELPHIA--(BUSINESS WIRE)--Iroko Pharmaceuticals, LLC today announced that the Phase 3 study evaluating the company’s investigational, lower dose submicron indomethacin in post-surgical acute pain met its primary endpoint of demonstrating significant pain relief compared with placebo. Full results from the study will be presented at a future medical meeting.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES